Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.39 |
| ▸ | FDPS | P14324 | 11/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19389271 | 0.82 | ALDH1A1 (0.43) | ALDH1A1GGPS1FDPSSMPD1CES2 | |
| SCHEMBL28651207 | 0.76 | ALDH1A1 (0.41) | ALDH1A1GGPS1FDPSSMPD1 | |
| SCHEMBL11399668 | 0.74 | ALDH1A1 (0.42) | ALDH1A1GGPS1FDPS | |
| SCHEMBL27848826 | 0.74 | ALDH1A1 (0.44) | ALDH1A1GGPS1FDPSSMPD1 | |
| SCHEMBL13411323 | 0.74 | ALDH1A1 (0.45) | ALDH1A1GGPS1FDPSSMPD1CES2 | |
| SCHEMBL31487362 | 0.73 | ALDH1A1 (0.46) | ALDH1A1FDPSSMPD1CES2 | |
| SCHEMBL15339686 | 0.73 | ALDH1A1 (0.46) | ALDH1A1FDPSCES2 | |
| SCHEMBL29596855 | 0.73 | ALDH1A1 (0.48) | ALDH1A1GGPS1FDPSSMPD1CES2 | |
| SCHEMBL11596859 | 0.73 | FDPS (0.43) | ALDH1A1GGPS1FDPSSMPD1CES2 | |
| SCHEMBL14167475 | 0.73 | FDPS (0.43) | ALDH1A1GGPS1FDPSSMPD1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1880027-B1 | COMPOSITION AND METHODS FOR CANCER DIAGNOSIS UTILIZING THE MIR 17-92 CLUSTER | COLD SPRING HARBOR LAB (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012068477-A1 | METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH | VASGENE THERAPEUTICS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-8153605-B2 | Modulation of toll-like receptor 3 expression by antisense oligonucleotides | IDERA PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153777-B2 | Modulation of toll-like receptor 5 expression by antisense oligonucleotides | IDERA PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8110365-B2 | Via detecting elevations in GSK3b levels (glycogen synthase kinase-4-beta); enzyme inhibitors; kits | RHODE ISLAND HOSPITAL (US) | 2012-02-07 | — | — | US | disclosed |
| US-8071559-B2 | Compositions and methods for cancer diagnosis and treatment | COLD SPRING HARBOR LABORATORY (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2365814-A1 | MODULATION OF TOLL-LIKE RECEPTOR 4 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES | Idera Pharmaceuticals, Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2352743-A2 | MODULATION OF TOLL-LIKE RECEPTOR 5 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES | Idera Pharmaceuticals, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2352527-A1 | MODULATION OF TOLL-LIKE RECEPTOR 2 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES | Idera Pharmaceuticals, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2341914-A2 | MODULATION OF TOLL-LIKE RECEPTOR 3 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES | Idera Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-1997048795-A2 | COMPOSITIONS AND METHODS FOR TREATING SPECIFIC GENE EXPRESSION-RELATED DISEASES AND DISORDERS IN HUMANS | HYBRIDON, INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997043404-A2 | RIBOZYME VARIANTS WITH IMPROVED CATALYTIC ACTIVITY UNDER LOW MAGNESIUM CONDITIONS | HYBRIDON, INC. (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997038097-A1 | COOPERATIVE OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| WO-1997025444-A1 | METHOD OF MONITORING PHARMACOKINETICS OF OLIGONUCLEOTIDE PHARMACEUTICALS | HYBRIDON, INC. (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5641756-A | SYNTHETIC OLIGONUCLEOTIDE COMPLEMENTARY TO NUCLEIC ACID SPECIFIC FOR HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR | HYBRIDON, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| WO-1997021808-A1 | MODIFIED VEGF ANTISENSE OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997020925-A1 | MODIFIED VEGF ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF SKIN DISORDERS | HYBRIDON, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
| WO-1996039500-A2 | OLIGONUCLEOTIDES SPECIFIC FOR HEPATITIS C VIRUS | HYBRIDON INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996032474-A1 | COOPERATIVE OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 1996-10-17 | — | — | WO | disclosed |
| WO-1996027006-A2 | HUMAN VEGF-SPECIFIC ANTISENSE OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 1996-09-06 | — | — | WO | disclosed |